SPARTAN Group

Spondyloarthritis Research and Treatment Network

  • Become a SPARTAN Member
  • Donate
  • Contact Us
  • Log In
  • Home
  • About Us
    • About Spondyloarthritis
    • About SPARTAN
    • Corporate Supporters
    • Leadership
    • Committees
    • Awards
    • SPARTAN Newsletter Archives
    • Bylaws
  • Membership
    • Become a SPARTAN Member
    • Member Directory
  • Annual Meeting
    • 2023 SPARTAN Annual Meeting
    • 2023 Spondyloarthritis Review Course
    • 2023 Call for Trainee Abstracts
  • Projects
    • SPARTAN Projects
    • CLASSIC Study
  • Grants
    • Early Career Investigator Award
      • Early Career Investigator Award Application
    • Mentored Fellowship Award
      • Mentored Fellowship Award Application Form
    • SPARTAN Overhead Policy
  • Education
    • SPARTAN GRAPPA ASAS Symposium
    • CAPES Education Series
    • GRAPPA SPARTAN Global Education Seminars
    • Case Library
    • Treatment Guidelines
  • Members
    • Password Reset
    • Log Out

Case Library—Pediatric Case 1

  • CASE LIBRARY ALL
  • Pediatric Case 1
  • Pediatric Case 2
  • Pediatric Case 3
  • Pediatric Case 4

Case 1

Author: Hemalatha Srinivasalu, MD

10-year-old female presents with joint pain over knees, heels, ankles, shoulders and neck over past 2-3 months. She has joint swelling, and morning stiffness. Pain increases with physical activity, using the stairs hurts her knees. She has pain over ribcage and pain with taking deep breaths. She was an avid soccer player and has had to stop playing due to pain.

Review of systems: Positive for decreased energy, oral ulcerations, abdominal pain, nausea, dysuria, eczema, psoriasis and headaches.

No significant past medical history.

Family history: Maternal grandmother – juvenile idiopathic arthritis (JIA) and thyroid disorder; Maternal aunt – kidney disease and thyroid disorder; Paternal grandfather: rheumatoid arthritis. No psoriasis, inflammatory bowel disease, celiac disease or lupus in the family

Immunizations: up to date

Allergies: no known drug allergies

Medications: Ibuprofen 400 mg three times daily

On examination:

Vital Signs: Normal.

General, head and neck, cardiovascular, respiratory, and neurologic systems: Normal.

Skin: No rashes. Normal nails.

Musculoskeletal system:
Joint exam: Areas shaded in blue in the homunculus had signs of active arthritis
Joint exam: Areas shaded in blue in the homunculus had signs of active arthritis. Abbreviations: T = Tender; S = Swelling
Entheseal exam: Blue dots indicate areas of active enthesitis
Entheseal exam: Blue dots indicate areas of active enthesitis
Swelling over Achilles insertion bilaterally
Swelling over Achilles insertion bilaterally

Investigations:
Labs – Normal ESR, CRP. ANA neg, RF neg, HLA B27 neg
X-rays of ankles, hands, knees and back – all normal

What form of juvenile idiopathic arthritis (JIA) does the patient have?

  1. Psoriatic JIA (JPsA)
  2. Polyarticular JIA
  3. Extended oligoarticular JIA
  4. Enthesitis related arthritis (ERA)
Correct Response:
4. Enthesitis related arthritis (ERA)

Explanation: JIA is classified according to the ILAR classification system (1) into 7 sub-types, each of which have a set of inclusion and exclusion criteria. Of these, enthesitis related arthritis, psoriatic arthritis and undifferentiated JIA fall under the spectrum of juvenile spondyloarthritis. ERA and PsA are mutually exclusive in this classification system. Incongruity of classification system with that of adult spondyloarthritis is confusing both in clinical practice and research. There is impetus to consider juvenile arthritis as a continuum of adult arthritis (2).

According to the ILAR criteria, the definition of ERA requires either

  1. Arthritis and Enthesitis; or
  2. Arthritis or Enthesitis plus two or more of the following: 1) sacroiliac joint tenderness and/or inflammatory spinal pain; 2) HLA-B27 positivity; 3) arthritis in a male over 6 years of age; 4) family history in ankylosing spondylitis, ERA, sacroiliitis with IBD, reactive arthritis; or acute anterior uveitis; or 5) acute anterior uveitis

Exclusions are: 1) Psoriasis or a history of psoriasis in the patient or first-degree relative; 2) Presence of RF on at least 2 occasions at least 3 months apart; 3) Systemic JIA

JPsA is defined as

  1. Arthritis and psoriasis; or
  2.  Arthritis plus at least 2 of the following: 1) Dactylitis; 2) Nail pitting or onycholysis; 3) Psoriasis in a first-degree relative.

Exclusions are: 1) Arthritis in an HLA-B27 positive male after 6 years of age; 2) Ankylosing spondylitis, ERA, sacroiliitis with IBD, reactive arthritis or acute anterior uveitis, or a history of one of these disorders in a first degree relative; 3) Presence of RF on at least 2 occasions at least 3 months apart; 4) Systemic JIA

She was started on naproxen 15 mg/kg/day by mouth twice daily and physical therapy. She continued to have active arthritis and enthesitis after 6 weeks on naproxen. She was having increasing difficulty ambulating and performing activities of daily living. She was hence started on oral prednisone 2 weeks ago as bridge therapy.

What should be the next step?

  1. Start a TNFi
  2. Continue systemic corticosteroids with plan to taper over 6 months
  3. Corticosteroid injection of affected joints and entheses
  4. Start a non-biologic DMARD such as Sulfasalazine or Methotrexate
Correct Response:
1. Start a TNFi

In 2019, ACR published guidelines for treatment of JIA (3). In children with JIA and active enthesitis despite treatment with NSAIDs, using a TNFi is conditionally recommended over methotrexate or sulfasalazine. While TNFi is preferred, a trial of methotrexate or sulfasalazine may be warranted in the following scenarios: a) contraindications to TNFi, b) mild enthesitis, and c) concomitant active peripheral polyarthritis. Use of systemic corticosteroids must be limited to less than 3 months as a bridging therapy during initiation or escalation of therapy. Bridging therapy may be of most benefit when patients have high disease activity, limited mobility, and/or significant symptoms.

Pediatric Case 1 Feedback

"*" indicates required fields

Your feedback will help us improve our case library to better serve in your understanding of the material.
How useful was this case study in contributing to your understanding of the material?*

References
  1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. The Journal of rheumatology. 2004;31(2):390-2.
  2. Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature reviews Rheumatology. 2021.
  3. Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis & rheumatology (Hoboken, NJ). 2019;71(6):846-63.

About US

About SPARTAN
Leadership
Committees
ByLaws

Keep in Touch with SPARTAN

Receive the SPARTAN email newsletter, published quarterly.

Browse newsletter archives.

Twitter @spartan_updates
SPARTAN on LinkedIn

Contact Us

SPARTAN Office
PO Box 55491
Portland, OR 97238

Copyright © 2023 SPARTAN · Log in